Rosemarie Gotshall, MD
Family Medicine · Sacaton, AZNPI 1831149509
Payments from drug & device makers
Across 269 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$567
- Pfizer$356
- GSK$308
- Astellas Pharma US Inc$280
- Lilly USA, LLC$240
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,947100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 78 | $1,008 |
| AstraZeneca | 22 | $567 |
| Pfizer | 18 | $356 |
| GSK | 19 | $308 |
| Astellas Pharma US Inc | 10 | $280 |
| Lilly USA, LLC | 19 | $240 |
| Abbott | 10 | $189 |
| Boehringer Ingelheim | 9 | $166 |
| Merck | 8 | $164 |
| Eisai Inc. | 7 | $162 |
| Shockwave Medical, Inc | 1 | $129 |
| Novartis | 5 | $113 |
| Sanofi-aventis U.S. LLC | 5 | $95 |
| Exact Sciences | 5 | $94 |
| Xeris Pharmaceuticals, Inc. | 4 | $89 |
| Abiomed | 2 | $85 |
| Medtronic | 4 | $81 |
| Johnson & Johnson | 5 | $76 |
| AbbVie(2 entities) | 3 | $70 |
| Sanofi Pasteur Inc. | 3 | $61 |
| Corcept Therapeutics | 2 | $54 |
| Phadia US Inc. | 2 | $48 |
| Lucid Diagnostics Inc. | 2 | $47 |
| Arbor Pharmaceuticals, Inc. | 3 | $47 |
| Teva Pharmaceuticals USA, Inc. | 2 | $46 |
| Amgen | 3 | $43 |
| Inspire Medical Systems, Inc. | 2 | $41 |
| Viiv Healthcare Company | 2 | $36 |
| Shield Therapeutics Inc | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Dexcom, Inc. | 2 | $29 |
| Amarin Pharma, Inc. | 2 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Vistapharm, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,947 in reported general payments places this provider in the 85th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 44 | $81,365 |
| EliquisApixaban | 39 | $45,174 |
| OzempicSemaglutide | 29 | $38,270 |
| JanuviaSitagliptin Phosphate | 30 | $36,814 |
| JardianceEmpagliflozin | 29 | $34,208 |
| MounjaroTirzepatide | 20 | $24,151 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $22,954 |
| XareltoRivaroxaban | 14 | $19,166 |
| TrulicityDulaglutide | 11 | $15,314 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $10,141 |
| Atorvastatin Calcium | 1,233 | $10,137 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $9,391 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $9,077 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 60 | $7,170 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $1,008 | $119,63573 claims |
| PfizerEliquis | $356 | $45,17439 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $308 | $41,42258 claims |
| Lilly USA, LLCMounjaro, Trulicity | $240 | $39,46531 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $166 | $39,43840 claims |
| MerckJanuvia | $164 | $36,81430 claims |
| Johnson & JohnsonXarelto | $76 | $19,16614 claims |
| AbbVieSynthroid | $70 | $2,02127 claims |
| Sanofi-aventis U.S. LLCLantus | $95 | $1,59412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Sacaton
- Danielle ArmasScottsdale$73M
- Terry O'ReillyMesa$35.8M
- Shawn SearleChandler$27M
- Corey AndersonMesa$21.5M
- Dena PetersenTucson$14.7M
- Gerald ShockeyMesa$12.3M
- Brock MerrittPhoenix$8.4M
- John McGettiganTucson$8.3M
- Neil ShethChandler$6.7M
- Joseph LilloScottsdale$6.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.